CN105968120B - Preparation method of tetrandrine and tetrandrine B - Google Patents

Preparation method of tetrandrine and tetrandrine B Download PDF

Info

Publication number
CN105968120B
CN105968120B CN201610366510.XA CN201610366510A CN105968120B CN 105968120 B CN105968120 B CN 105968120B CN 201610366510 A CN201610366510 A CN 201610366510A CN 105968120 B CN105968120 B CN 105968120B
Authority
CN
China
Prior art keywords
tetrandrine
components
chromatographic column
preparation
sample injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201610366510.XA
Other languages
Chinese (zh)
Other versions
CN105968120A (en
Inventor
付少彬
杨鸿强
孟庆峰
张茂生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zunyi Medical University
Original Assignee
Zunyi Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zunyi Medical University filed Critical Zunyi Medical University
Priority to CN201610366510.XA priority Critical patent/CN105968120B/en
Publication of CN105968120A publication Critical patent/CN105968120A/en
Application granted granted Critical
Publication of CN105968120B publication Critical patent/CN105968120B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention discloses a preparation method of tetrandrine and tetrandrine, which belongs to the technical field of medicine preparation, and is prepared by adopting lipophilic tertiary amine total alkali through 2 steps, 1) separating by using a medium-pressure silica gel chromatographic column method, and eluting by using petroleum ether-ethyl acetate-diethylamine; 2) and purifying by combining with preparative high performance liquid chromatography, taking methanol-water as a mobile phase, and finally respectively concentrating and evaporating eluent to dryness.

Description

Preparation method of tetrandrine and tetrandrine B
Technical Field
The invention relates to a preparation method of a medicament, in particular to a preparation method of tetrandrine and tetrandrine.
Background
Radix Stephaniae Tetrandrae, rhizoma Stephaniae Tetrandrae, Bufo siccus, and herba Ardisiae Japonicae are dry root tuber of radix Stephaniae Tetrandrae of Stephania of Menispermaceae, and contain polysaccharide, alkaloid, etc., and its main effective components are tetrandrine and tetrandrine. Tetrandrine has antiinflammatory, analgesic, blood pressure lowering, antitumor, anti-hypoxic pulmonary hypertension, and pulmonary fibrosis inhibiting effects. Tetrandrine is a natural calcium antagonist, and has therapeutic effect on hypertension, diabetes, hepatic fibrosis, etc., and also has brain cell protecting effect and broad-spectrum antiinflammatory and antibacterial effects. The existing method for preparing tetrandrine and tetrandrine has the common defects of complex process, high production cost and low preparation efficiency.
Disclosure of Invention
The invention aims to overcome the defects of complex process and high preparation cost of the existing method and provide a novel preparation method of tetrandrine and tetrandrine.
In order to achieve the purpose, the technical scheme is as follows:
a method for preparing tetrandrine and tetrandrine B comprises the following steps:
1) separating tetrandrine and tetrandrine by medium pressure silica gel chromatography, loading a column with volume of 49mm × 460mm, loading lipophilic tertiary amine total alkali into the column, eluting with petroleum ether-ethyl acetate-diethylamine at flow rate of 80 mL/min, collecting eluate, inspecting by TLC, mixing the same components, recovering solvent to obtain two components Fr 1 and Fr 2;
2) preparing high performance liquid chromatography for purifying tetrandrine and tetrandrine: and (2) aiming at the components Fr 1 and Fr 2, adopting a YMC-pack chromatographic column 250 x 10mmD, S-5 mu m and 12 nm, selecting 230 nm as a detection wavelength, the flow rate of 4 mL/min and methanol-water as a mobile phase, carrying out sample injection separation, collecting the separated eluates of two main peaks, and respectively concentrating and evaporating the eluates to dryness to obtain the compound.
Further, in the step 1), the silica gel used by the chromatographic column is 300-400 mesh.
Further, in the step 1), the ratio of petroleum ether-ethyl acetate-diethylamine is 9:1:0.1-5:1: 0.1.
Further, in the step 1), the solvent is recovered by using a rotary evaporator.
Further, in the step 2), the components Fr 1 and Fr 2 are filtered by a 0.22 μm microporous filter membrane before being injected.
Further, in the step 2), the ratio of methanol to water is 17: 3.
Further, in the step 2), the sample injection amount is 0.5 mL.
The beneficial effect who adopts above-mentioned scheme does: the tetrandrine and the tetrandrine B prepared by combining the medium-pressure silica gel chromatographic column method with the high performance liquid chromatography have the advantages of convenience and rapidness in operation and high purity, and two products can be obtained by one preparation method, so that the extraction rate is high.
Drawings
FIG. 1 is the TLC bismuth potassium iodide and TLC 254nm purple outer color chart of tetrandrine and tetrandrine B prepared by the embodiment of the invention.
FIG. 2 shows tetrandrine prepared according to the present invention1H-NMR chart.
FIG. 3 shows the preparation of tetrandrine1H-NMR chart.
Detailed Description
The present invention is further described with reference to the following embodiments and drawings, but the present invention is not limited to the following embodiments, and it is anticipated that one skilled in the art may make various changes in the embodiments in combination with the prior art.
A method for preparing tetrandrine and tetrandrine B comprises the following steps:
1) the method for separating tetrandrine and tetrandrine B by medium pressure silica gel chromatographic column comprises loading a chromatographic column with volume of 49mm × 460mm, wherein silica gel used in the chromatographic column is 300-400 mesh, loading lipophilic tertiary amine total alkali into the column, eluting with petroleum ether-ethyl acetate-diethylamine (9:1:0.1-5:1: 0.1) at flow rate of 80 mL/min, detecting the collected eluate by TLC, mixing the components, recovering solvent with rotary evaporator to obtain two main components Fr 1 and Fr 2 with high content of tetrandrine and tetrandrine B respectively.
2) And preparing high performance liquid chromatography for purifying tetrandrine and tetrandrine: adopting YMC-pack chromatographic column (250 x 10mmD, S-5 μm,12 nm), selecting 230 nm as detection wavelength, flow rate of 4 mL/min, methanol (A) -water (B) as mobile phase, and continuously adjusting methanol (A) -water (B) ratio and sample amount (sample passes through 0.22 μm microporous filter membrane before sample injection). Until a suitable chromatographic condition is found, the ratio of the methanol to the water is 85 percent to 15 percent, the sample amount is 0.5 mL, the peak pattern is better, and the separation degree is high. The eluate of the two main peaks obtained by separation was collected and the remaining components were discarded. And (3) concentrating and evaporating the collected eluent respectively, dissolving a proper amount of product with methanol, comparing TLC (thin layer chromatography) with a standard substance, and performing chromatography with petroleum ether: ethyl acetate: diethylamine (3: 2: 1) as developing agent, and bismuth potassium iodide as color developing agent. Inspection under 254nm UV.
The tetrandrine and tetrandrine B prepared by the invention have the same spot color and position with the reference substance, and have single component. As shown in FIG. 1, TLC bismuth potassium iodide chromogenic diagram is arranged on the left side, Han TLC 254nm purple outer chromogenic diagram is arranged on the right side, and tetrandrine, tetrandrine standard substance, tetrandrine and tetrandrine standard substance are arranged on the spots from left to right in sequence.
As shown in figure 2, the prepared tetrandrine1H-NMR results: a white-like powder.1H-NMR(400 MHz, CDCl3):2.33(s,3H), 2.41 ~ 2.47(m, 1H),2.52(d,J=12.0 Hz, 1H), 2.62( s, 3H), 3.19(s,3H), 3.25(dd,J=12.0,8.0 Hz, 1H), 3.37(s, 3H), 3.43~3.48(m, 1H), 3.51~3.56(m, 1H), 3.75(s, 3H), 3.88(dd,J=12.0,4.0Hz, 1H), 3.93(s,3H), 5.99(s, 1H),6.29(s, 1H), 6.30(m, 2H), 6.51(s,1H), 6.55(s, 1H), 6.81(d,J=8.0 Hz, 1H),6.86(dd,J=8.0, 4.0 Hz, 1H), 6.87(s, 1H), 6.89(s, 1H), 7.13(dd,J=8.0, 4.0Hz, 1H), 7.34(d,J=8.0 Hz, 1H) 。
As shown in figure 3, the obtained tetrandrine is white powder.1H-NMR(400 MHz, CDCl3): 2.33(s,3H),2.41 ~ 2.45(m, 2H),2.56(d,J=16.0 Hz, 1H), 2.63( s, 3H), 3.26(dd,J=12.0,8.0 Hz, 1H), 3.35(s, 3H), 3.48~3.54(m, 2H), 3.77(s, 3H), 3.88-3.91(m, 1H),3.92(s,3H), 6.05(s, 1H), 6.29(s, 1H), 6.32(m, 1H), 6.52(s,1H), 6.56(s, 1H),6.81(d,J=8.0 Hz, 1H), 6.86(o, 1H), 6.87(o, 1H), 6.89(o, 1H), 7.13(dd,J=8.0,4.0 Hz, 1H), 7.34(d,J=8.0 Hz, 1H) 。
The tetrandrine and the tetrandrine are different from each other in the substituent group at the 7-position, wherein the tetrandrine is methoxy, and the tetrandrine is phenolic hydroxyl. In that1In H-NMR, 4 methoxy signals, 3.19(s, 3H, H-7), 3.37(s, 3H, H-6 ´)3.75(s, 3H, H-6), 3.93(s,3H, H-12) were present between 3.0 and 4.0, whereas in hanfangchin, only 3 methoxy signals, 3.35(s,3H), 3.77(s, 3H), 3.92(s, 3H), were present at positions 6, 6 and 12, respectively, so that the signal was derived from 6 ´, 6 and 12, respectively1The element A and the element B can be easily distinguished by H-NMR.

Claims (1)

1. A preparation method of tetrandrine and tetrandrine B is characterized by comprising the following steps:
1) loading a chromatographic column with the volume of 49mm × 460mm, loading lipophilic tertiary amine total alkali into the chromatographic column, eluting by petroleum ether-ethyl acetate-diethylamine with the flow rate of 80 mL/min, collecting eluent, inspecting by TLC, merging the same components, recovering the solvent by using a rotary evaporation instrument to obtain two components Fr 1 and Fr 2, wherein the silica gel used by the chromatographic column is 300-mesh and 400-mesh;
2) preparing high performance liquid chromatography for purifying tetrandrine and tetrandrine: adopting YMC-pack chromatographic columns 250 x 10mmD, S-5 mu m and 12 nm aiming at the components Fr 1 and Fr 2, selecting 230 nm as a detection wavelength, the flow rate of 4 mL/min and methanol-water as a mobile phase, carrying out sample injection separation, collecting the eluates of two main peaks obtained by separation, and respectively concentrating and evaporating the eluates to dryness to obtain the compound preparation; the ratio of the methanol to the water is 17: 3; filtering the components Fr 1 and Fr 2 with a 0.22 μm microporous filter membrane before sample injection; the sample injection amount is 0.5 mL.
CN201610366510.XA 2016-05-30 2016-05-30 Preparation method of tetrandrine and tetrandrine B Expired - Fee Related CN105968120B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610366510.XA CN105968120B (en) 2016-05-30 2016-05-30 Preparation method of tetrandrine and tetrandrine B

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610366510.XA CN105968120B (en) 2016-05-30 2016-05-30 Preparation method of tetrandrine and tetrandrine B

Publications (2)

Publication Number Publication Date
CN105968120A CN105968120A (en) 2016-09-28
CN105968120B true CN105968120B (en) 2020-07-03

Family

ID=56955696

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610366510.XA Expired - Fee Related CN105968120B (en) 2016-05-30 2016-05-30 Preparation method of tetrandrine and tetrandrine B

Country Status (1)

Country Link
CN (1) CN105968120B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111153909B (en) * 2020-01-17 2022-05-17 石药集团江西金芙蓉药业股份有限公司 A double-template molecular imprinting purification method for alpha-and beta-carotene in Stephania tetrandra

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1850824A (en) * 2006-04-27 2006-10-25 富力 Benzene-free tetrandrine and its preparing method
CN101012229A (en) * 2007-01-26 2007-08-08 北海阳光药业有限公司 Hanfangchin A without benzene and chloroform and preparing method thereof
CN101033229A (en) * 2007-02-09 2007-09-12 南开大学 Separation of monosomic tetrandrine from tetrandrine total alkaloid by adsorption resin method
CN101288695A (en) * 2007-04-16 2008-10-22 中国科学院成都生物研究所 Preparation technique of alkaloids from Stephania tetrandra

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1850824A (en) * 2006-04-27 2006-10-25 富力 Benzene-free tetrandrine and its preparing method
CN101012229A (en) * 2007-01-26 2007-08-08 北海阳光药业有限公司 Hanfangchin A without benzene and chloroform and preparing method thereof
CN101033229A (en) * 2007-02-09 2007-09-12 南开大学 Separation of monosomic tetrandrine from tetrandrine total alkaloid by adsorption resin method
CN101288695A (en) * 2007-04-16 2008-10-22 中国科学院成都生物研究所 Preparation technique of alkaloids from Stephania tetrandra

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TLC法分离汉防己中汉防己甲素、乙素;徐应淑 等;《遵义医学院学报》;20090630;第32卷(第3期);第296-297页,第2.2.2节和3.3节 *

Also Published As

Publication number Publication date
CN105968120A (en) 2016-09-28

Similar Documents

Publication Publication Date Title
CN103145677B (en) Method for separating active ingredients from aquilaria sinensis lamina by utilizing high-speed countercurrent chromatography
CN101559088A (en) Production technique of andrographolide and neoandrographolide, dehydroanddrographolide, oxyandrographolide
CN102285982B (en) Method for separating and purifying monomer compounds from Chinese medicinal herb rhizoma coptidis
CN101863935B (en) Preparation method of 1,4-di-[4-(glucosyloxy) benzyl]-2-isobutyl malate comparison product
CN102617669B (en) Method for separating and purifying mangiferin from mango pericarp
CN101525328B (en) Method for extracting alpha-mangostin from mangosteen fruit peel
CN101260138B (en) Highly effective separation purification method for polygalic acid and tenuigenin
CN105968120B (en) Preparation method of tetrandrine and tetrandrine B
CN108840845A (en) The method of Xanthatin is extracted from Siberian cocklebur
CN106226426A (en) A kind of high performance liquid chromatography splits the method for canagliflozin five-membered ring impurity enantiomer
CN105585600A (en) Preparation method of secoxyloganin
CN104829474A (en) Method for preparing glycine betaine chemical reference substances from boxthorn leaves
CN107573255A (en) A kind of method that capsaicine and dihydrocapsaicin are isolated and purified from pepper fruit
CN107629065A (en) A kind of method of separation and concentration furoquinoline Alkaloid in skin from Dictamnus angustifolius
CN108440612A (en) The isolation and purification method of three kinds of iridoid constituents in a kind of radix scrophulariae
CN109400566A (en) A method of extracting separating high-purity amentoflavone from Rock lily plant
CN109912582A (en) The method of mangiferin is extracted from mango leaf
CN104926659A (en) Method for preparing rosmarinic acid chemical reference substance from three types of high mountain salvias
CN108997359A (en) A method of chlorophyll is extracted from stevioside production waste residue
CN104844547B (en) A kind of high efficiency extraction of barbaloin and grading purification method
CN105061212B (en) A kind of preparation method of neochlorogenic acid
CN106946833A (en) A kind of method that high-purity sinensetin is extracted from Mao Xu Cao
CN102911221A (en) Method for industrially preparing geniposide from gardenia
CN104892703B (en) It is a kind of to prepare rutin, the method for Quercetin chemical reference substance simultaneously from folium lycii
CN105016982B (en) Method for extracting, separating and purifying honokiol and magnolol from magnolia officinalis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200703

CF01 Termination of patent right due to non-payment of annual fee